ReviewCells2022
Dual Immune Regulatory Roles of Interleukin-33 in Pathological Conditions.
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- MicroRNAs and Alarmins in Cardio-Oncology: Biomarkers and Therapeutic Implications in Skin and Breast Cancer.International journal of molecular sciences · 2026Review
- Dissociation Between Functional Performance and Structural Joint Damage Following Sertraline Treatment in Collagen-Induced Arthritis.International journal of molecular sciences · 2026Article
- Diagnostic and monitoring value of serum interleukin-33 and rs16924159 polymorphism in relation to disease activity and tumor necrosis factor inhibitor response in rheumatoid arthritis.Journal of rheumatic diseases · 2026Article
- Circulating IL-33 as a sensitive alarmin in systemic lupus erythematosus: a biomarker for disease activity and skin-specific manifestations.Scientific reports · 2026Article
- Transcriptomic and functional comparison of adipose-and bone marrow-derived mesenchymal stem cells for tendon regeneration.Stem cell research & therapy · 2026Article
- Beyond the alarm: unveiling the multifaceted role of IL-33 in kidney disease.Frontiers in immunology · 2026Review
- Oligodendrocyte-derived IL-33 regulates self-reactive CD8+ T cells in CNS autoimmunity.The Journal of experimental medicine · 2025Article
- Dynamics of inflammatory signals within the tumor microenvironment.World journal of experimental medicine · 2025Review
- Biological mechanisms and therapeutic prospects of interleukin-33 in pathogenesis and treatment of allergic disease.Journal of inflammation (London, England) · 2025Review
- Interleukin-33 and Obesity-Related Inflammation and Cancer.Encyclopedia · 2024Article
- IL-33 Induces Cellular and Exosomal miR-146a Expression as a Feedback Inhibitor of Mast Cell Function.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Unveiling the multifaceted antitumor effects of interleukin 33.Frontiers in immunology · 2024Review
- Decoding the IL-33/ST2 Axis: Its Impact on the Immune Landscape of Breast Cancer.International journal of molecular sciences · 2023Review
- Eosinophils in the tumor microenvironment: implications for cancer immunotherapy.Journal of translational medicine · 2023Review
- Article
- Early activation and recruitment of invariant natural killer T cells during liver ischemia-reperfusion: the major role of the alarmin interleukin-33.Frontiers in immunology · 2023Article
- Are IL-1 family cytokines important in management of sickle cell disease in Sub-Saharan Africa patients?Frontiers in immunology · 2023Article
- Molecular Mechanisms Underlying IL-33-Mediated Inflammation in Inflammatory Bowel Disease.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-33 (IL-33), a member of the IL-1 cytokine family and a multifunctional cytokine, plays critical roles in maintaining host homeostasis and in pathological conditions, such as allergy, infectious diseases, and cancer, by acting on multiple types of immune cells and promoting type 1 and 2 immune responses. IL-33 is rapidly released by immune and non-immune cells upon stimulation by stress, acting as an "alarmin" by binding to its receptor, suppression of tumorigenicity 2 (ST2), to trigger downstream signaling pathways and activate inflammatory and immune responses. It has been recognized that IL-33 displays dual-functioning immune regulatory effects in many diseases and has both pro- and anti-tumorigenic effects, likely depending on its primary target cells, IL-33/sST2 expression levels, cellular context, and the cytokine microenvironment. Herein, we summarize our current understanding of the biological functions of IL-33 and its roles in the pathogenesis of various conditions, including inflammatory and autoimmune diseases, infections, cancers, and cases of organ transplantation. We emphasize the nature of context-dependent dual immune regulatory functions of IL-33 in many cells and diseases and review systemic studies to understand the distinct roles of IL-33 in different cells, which is essential to the development of more effective diagnoses and therapeutic approaches for IL-33-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.